Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab

Bone Marrow Transplantation volume 46, pages 262–266 (2011)Cite this article

Subjects

Abstract

The standard approach for relapsed diffuse large B-cell lymphoma (DLBCL) involves auto-SCT. However, studies that established this approach were conducted before the inclusion of rituximab (R) with first-line therapy became routine. Whether DLBCL patients (pts) relapsing after first-line chemoimmunotherapy including R derive a comparable benefit from auto-SCT to pts in the pre-R era is unknown. We analyzed outcomes after auto-SCT for relapsed DLBCL among pts receiving initial R and those who did not. We reviewed 257 consecutive pts with relapsed DLBCL treated at our institution with auto-SCT. In all, 226 pts were included in the analysis, of whom 161 had received no R and 65 received R as part of first-line therapy (Planned R). Median OS and relapse-free survival, measured from transplant, were similar between No R vs Planned R groups: 67 vs 44 months (P=0.3) and 25 vs 27 months (P=0.8), respectively. A further analysis was carried out between two cohorts matched by propensity analysis. Again, no differences in outcomes were observed. This suggests that auto-SCT may be equally effective in pts relapsing after first-line therapy including R, and should remain the standard of care for relapsed DLBCL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Armitage JO, Weisenberger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphomas Classification Project. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  Google Scholar 

  2. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  Google Scholar 

  3. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126.

    Article  CAS  Google Scholar 

  4. Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391.

    Article  CAS  Google Scholar 

  5. Sehn L, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033.

    Article  CAS  Google Scholar 

  6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  7. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264–3269.

    Article  CAS  Google Scholar 

  8. Jaffe E, Harris N, Diebold J, Müller-Hermelink H . World Health Organization Classification of lymphomas: a work in progress. Ann Oncol 1998; 9 (Suppl 5): S25–S30.

    Article  Google Scholar 

  9. Rosenbaum P, Rubin D . The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55.

    Article  Google Scholar 

  10. Parsons L . Reducing bias in a propensity score-matched-pair sample using greedy matching techniques. SAS Users Group International Conference 2001. SAS Institute, Inc.: Cary, NC.

    Google Scholar 

  11. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M . R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009; 27: 15s(suppl; abstract 8509).

    Article  Google Scholar 

  12. Veelken H, Dannheim S, Moenting J, Martens U, Finke J, Schmitt-Graeff A . Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 2007; 18: 931–939.

    Article  CAS  Google Scholar 

  13. Vitolo U, Botto B, Capello D, Vivenza D, Zagonel V, Gloghini A et al. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. Leukemia 2002; 16: 268–275.

    Article  CAS  Google Scholar 

  14. Hallack Neto AE, Dulley FL, Coelho Siqueira SA, Pracchia LF, Belesso M, Saboya R et al. Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. Bone Marrow Transplant 2008; 43: 323–325.

    Article  Google Scholar 

  15. Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008; 142: 404–412.

    Article  Google Scholar 

  16. Moskowitz CH, Zelenetz AD, Kewalramani T, Hamlin P, Lessac-Chenen S, Houldsworth J et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005; 106: 3383–3385.

    Article  CAS  Google Scholar 

  17. Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930–4935.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA

    S D Smith, B J Bolwell, T Kang, R Dean, A Advani, S Thakkar, R Sobecks, M Kalaycio, B Pohlman & J W Sweetenham

  2. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA

    L A Rybicki

Authors
  1. S D Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B J Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L A Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Advani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Thakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J W Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S D Smith.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, S., Bolwell, B., Rybicki, L. et al. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplant 46, 262–266 (2011). https://doi.org/10.1038/bmt.2010.95

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.95

Keywords

This article is cited by

Search

Advanced search

Quick links